{"analyses":[{"ciLowerLimit":"1.202","ciPctValue":"95","ciUpperLimit":"4.356","estimateComment":"Afatinib 40 mg-Pemetrexed/Cisplatin Chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0118","paramType":"Odds Ratio (OR)","paramValue":"2.288","statisticalComment":"Logistic regression stratified for EGFR mutation group and race.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.9","upperLimit":"93.9","value":"90.4"},{"groupId":"OG001","lowerLimit":"72.5","upperLimit":"87.6","value":"80.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"DC was defined as a patient with OR or Stable Disease (SD). Assessed by central independent review according to the RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"NUMBER","populationDescription":"RS.","reportingStatus":"POSTED","timeFrame":"Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression","title":"Percentage of Participants With Disease Control (DC)","type":"SECONDARY","unitOfMeasure":"Percentage of participants with DC."}